NCT02023190

Brief Summary

Liver transplant is the goal treatment for every patient with end-stage chronic liver disease. Quality of life improves after transplant because the main complications of end-stage liver disease disappear, but due to immunosuppression other alterations appear such as metabolic alterations, weight gain, among others. Body composition and nutritional status can be affected do to post-transplant pharmacologic therapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2013

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 30, 2013

Completed
5 years until next milestone

Study Start

First participant enrolled

January 3, 2019

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

March 2, 2020

Status Verified

February 1, 2020

Enrollment Period

1.9 years

First QC Date

December 18, 2013

Last Update Submit

February 27, 2020

Conditions

Keywords

liver cirrhosisliver transplantnutritional statusbioelectrical impedance vector analysis

Outcome Measures

Primary Outcomes (1)

  • Body composition

    Body composition will be assessed through bioelectrical impedance vector analysis graph.

    Baseline, 7 days, 1 month, 3 months and 6 months post-tranpslant

Secondary Outcomes (1)

  • Liver function tests

    Baseline, 7 days, 1 month, 3 months and 6 months post-tranpslant

Study Arms (1)

Nutritional assessment

Nutritional assessment will be performed by bioelectrical impedance vector analysis

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients will be selected from the transplant enrollment list at the Department of Gastroenterology in a tertiary care center in Mexico

You may qualify if:

  • Liver cirrhosis (any etiology)
  • Enrolled in waiting list for tliver transplant

You may not qualify if:

  • Hepatocellular carcinoma
  • Chronic renal failure
  • Congestive cardiac failure
  • Extremity amputation
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City, Mexico City, 14000, Mexico

RECRUITING

MeSH Terms

Conditions

Liver Cirrhosis

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Aldo Torre, MD MSci

    Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    STUDY CHAIR
  • Astrid Ruiz-Margáin, M.Sci

    Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Aldo Torre, MD MSci

CONTACT

Astrid Ruiz-Margain, M.Sci

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

December 18, 2013

First Posted

December 30, 2013

Study Start

January 3, 2019

Primary Completion

December 1, 2020

Study Completion

December 1, 2022

Last Updated

March 2, 2020

Record last verified: 2020-02

Locations